罗格列酮对SHR大鼠降压作用和靶器官保护机制研究  

Study of the depressurization effect of rosiglitazone and its protection on the target organs of spontaneously hypertensive rats

作　　者：陈海燕[1] 李杰[1] 梁虹霞[1] 孔俭[1] 杨玉双[2] 

机构地区：[1]吉林大学第一医院干部病房 [2]吉林大学中日联谊医院心内科

出　　处：《中国老年学杂志》2007年第20期1970-1973,共4页Chinese Journal of Gerontology

基　　金：吉林省科技厅资助课题(20010517)

摘　　要：目的评价胰岛素增敏剂罗格列酮对原发性高血压大鼠的血压和血管紧张素Ⅱ受体1、AT1、的影响,探讨罗格列酮降低自发性高血压(SHR)大鼠血压和靶器官保护的作用机制。方法SHR大鼠36只,随机分成3组,分别给予罗格列酮、硝苯吡啶口服,并设空白对照。观察期8w。采用尾动脉血压间接测量法定期测血压,采用原位杂交和免疫组化检测大鼠心肌AT1mRNA和蛋白表达水平。结果罗格列酮及硝苯吡啶可以明显降低SHR大鼠血压,罗格列酮可抑制心肌AT1mRNA和蛋白表达水平。硝苯吡啶对AT1mRNA和蛋白质表达的影响不显著。结论罗格列酮可能通过纠正胰岛素抵抗抑制AT1mRNA和受体表达,发挥降压作用和靶器官保护作用。Objective To evaluate the effects of rosiglitazone （euglycemic agent） on the blood pressure （ BP）, angiotensin Ⅱ receptor 1 （ AT1 ） and explore its mechanisms of lowering the BP and protecting target organ of spontaneously hypertensive rats （SHRs）. Methods 36 SHR rats were divided into rosiglitazone, nifedipine and blank groups. The duration of observation was 8 weeks. The indirect tail measurement was used to measure BP. The hybridization in situ and the immunohistochemical methods were used to estimate the expression of the AT1 mRNA and protein in myocardium of all rats. Results Both rosiglitazone and nifedipine reduced BP significantly. Indeed, rosiglitazone inhibited the expression of AT1 mRNA and protein in myocardium of SHRs. But nifedipine had no obvious effect on the expression of AT1 mRNA and protei. Condusious Rosiglitazone could reduce BP and protect the organ injuries of hypertension through inhibiting the expression of AT1 mRNA and AT1 and Correcting insulin resistance.

关 键 词：罗格列酮 自发性高血压大鼠 血管紧张素Ⅱ受体1(AT1) 

分 类 号：R544.1[医药卫生—心血管疾病]